Absci (NASDAQ:ABSI) Stock Price Up 10.6% Following Analyst Upgrade

Posted by Brian Himes on May 30th, 2026

Absci Corporation (NASDAQ:ABSI – Get Free Report)’s stock price traded up 10.6% during mid-day trading on Thursday after BTIG Research upgraded the stock to a strong-buy rating. The company traded as high as $5.65 and last traded at $5.7050. 1,910,863 shares changed hands during mid-day trading, a decline of 52% from the average session volume of 4,017,772 shares. The stock had previously closed at $5.16.

Several other brokerages also recently issued reports on ABSI. Weiss Ratings reiterated a “sell (d-)” rating on shares of Absci in a research report on Monday, April 20th. Needham & Company LLC restated a “buy” rating and set a $7.00 target price on shares of Absci in a report on Wednesday, March 25th. Morgan Stanley set a $4.10 target price on Absci in a research note on Thursday, May 14th. Finally, Truist Financial lifted their price target on Absci from $9.00 to $11.00 and gave the company a “buy” rating in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $7.82.

Check Out Our Latest Stock Analysis on Absci

Insider Buying and Selling

In other news, insider Andreas Busch acquired 100,000 shares of the company’s stock in a transaction on Thursday, March 12th. The stock was purchased at an average cost of $2.29 per share, with a total value of $229,000.00. Following the acquisition, the insider owned 421,446 shares of the company’s stock, valued at $965,111.34. This trade represents a 31.11% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.49% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Absci

A number of institutional investors and hedge funds have recently modified their holdings of the business. Essential Partners LLC lifted its holdings in Absci by 113,850.0% in the first quarter. Essential Partners LLC now owns 9,116 shares of the company’s stock valued at $27,000 after buying an additional 9,108 shares during the period. Bank of America Corp DE grew its holdings in Absci by 55.2% during the 1st quarter. Bank of America Corp DE now owns 487,193 shares of the company’s stock worth $1,462,000 after acquiring an additional 173,361 shares during the period. Royal Bank of Canada raised its position in shares of Absci by 29.7% during the 1st quarter. Royal Bank of Canada now owns 175,085 shares of the company’s stock valued at $525,000 after acquiring an additional 40,111 shares during the last quarter. Siren L.L.C. bought a new stake in shares of Absci during the 1st quarter valued at $5,400,000. Finally, Principal Financial Group Inc. bought a new position in shares of Absci in the 1st quarter worth $31,000. 52.05% of the stock is owned by institutional investors.

Absci Price Performance

The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -8.13 and a beta of 2.36. The business has a 50 day moving average of $4.18 and a 200 day moving average of $3.45.

Absci (NASDAQ:ABSI – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.01. The business had revenue of $0.22 million during the quarter, compared to analyst estimates of $1.39 million. Absci had a negative return on equity of 66.32% and a negative net margin of 6,450.76%. As a group, equities analysts predict that Absci Corporation will post -0.77 EPS for the current year.

Absci Company Profile

(Get Free Report)

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.